This study by Wilfred De Vega et. al. has been discussed before on the forums, I think, but here it is again
https://pubmed.ncbi.nlm.nih.gov/28231836/
. 2017 Feb 23;10(1):11.
doi: 10.1186/s12920-017-0248-3.
Epigenetic Modifications and Glucocorticoid Sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Wilfred C de Vega 1 2, Santiago Herrera 1 3, Suzanne D Vernon 4 5, Patrick O McGowan 6 7 8 9
Affiliations
Abstract
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating idiopathic disease characterized by unexplained fatigue that fails to resolve with sufficient rest. Diagnosis is based on a list of symptoms and exclusion of other fatigue-related health conditions. Despite a heterogeneous patient population, immune and hypothalamic-pituitary-adrenal (HPA) axis function differences, such as enhanced negative feedback to glucocorticoids, are recurring findings in ME/CFS studies. Epigenetic modifications, such as CpG methylation, are known to regulate long-term phenotypic differences and previous work by our group found DNA methylome differences in ME/CFS, however the relationship between DNA methylome modifications, clinical and functional characteristics associated with ME/CFS has not been examined.
https://pubmed.ncbi.nlm.nih.gov/28231836/
. 2017 Feb 23;10(1):11.
doi: 10.1186/s12920-017-0248-3.
Epigenetic Modifications and Glucocorticoid Sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Wilfred C de Vega 1 2, Santiago Herrera 1 3, Suzanne D Vernon 4 5, Patrick O McGowan 6 7 8 9
Affiliations
- PMID: 28231836
- PMCID: PMC5324230
- DOI: 10.1186/s12920-017-0248-3
Abstract
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating idiopathic disease characterized by unexplained fatigue that fails to resolve with sufficient rest. Diagnosis is based on a list of symptoms and exclusion of other fatigue-related health conditions. Despite a heterogeneous patient population, immune and hypothalamic-pituitary-adrenal (HPA) axis function differences, such as enhanced negative feedback to glucocorticoids, are recurring findings in ME/CFS studies. Epigenetic modifications, such as CpG methylation, are known to regulate long-term phenotypic differences and previous work by our group found DNA methylome differences in ME/CFS, however the relationship between DNA methylome modifications, clinical and functional characteristics associated with ME/CFS has not been examined.
Last edited by a moderator: